-
1Academic Journal
Συγγραφείς: O. V. Finleyson, О. В. Финлейсон
Πηγή: Neuromuscular Diseases; Том 15, № 1 (2025); 61-66 ; Нервно-мышечные болезни; Том 15, № 1 (2025); 61-66 ; 2413-0443 ; 2222-8721
Θεματικοί όροι: иммунные побочные эффекты, myocarditis, myositis, immune checkpoint inhibitors, thymoma, immune-related adverse effects, миокардит, миозит, ингибиторы иммунной контрольной точки, тимома
Περιγραφή αρχείου: application/pdf
Relation: https://nmb.abvpress.ru/jour/article/view/649/415; Kaminski H.J., Sikorski P., Coronel S.I., Kusner L.L. Myasthenia gravis: The future is here. J Clin Invest 2024;134(12):e179742. DOI:10.1172/JCI179742; Safa H., Johnson D.H., Trinh V.A. et al. Immune checkpoint inhibitor related myasthenia gravis: Single center experience and systematic review of the literature. J Immunother Cancer 2019;7(1):319. DOI:10.1186/s40425-019-0774-y; Wang D.Y., Salem J.E., Cohen J.V. et al. Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta-analysis. JAMA Oncol 2018;4(12):1721–8. DOI:10.1001/jamaoncol.2018.3923; Dalakas M.C. Neurological complications of immune checkpoint inhibitors: What happens when you ‘take the brakes off’ the immune system. Ther Adv Neurol Disord 2018;11:1756286418799864. DOI:10.1177/1756286418799864; Suzuki S., Ishikawa N., Konoeda F. et al. Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. Neurology 2017;89(11):1127–34. DOI:10.1212/WNL.0000000000004359; Moslehi J.J., Salem J.E., Sosman J.A. et al. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet 2018;391(10124):933. DOI:10.1016/S0140-6736(18)30533-6; Wu J., Fang W., Chen G. The enlightenments from ITMIG Consensus on WHO histological classification of thymoma and thymic carcinoma: Refined definitions, histological criteria, and reporting. J Thorac Dis 2016;8(4):738–43. DOI:10.21037/jtd.2016.01.84; Ruffini E., Huang J., Cilento V. et al. The International Association for the Study of Lung Cancer Thymic Epithelial Tumors Staging Project: Proposal for a Stage Classification for the Forthcoming (Ninth) Edition of the TNM Classification of Malignant Tumors. J Thorac Oncol 2023;18(12):1655–71. DOI:10.1016/j.jtho.2023.09.002; МЕДИУМ. Справочник лекарственных препаратов. Пемброриа. Доступно по: https://medum.ru/pembroria-pembrolizumab.; Abdel-Wahab N., Shah M., Lopez-Olivo M.A., Suarez-Almazor M.E. Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: A systematic review. Ann Intern Med 2018;168(2):121–30. DOI:10.7326/M17-2073; Brahmer J.R., Lacchetti C., Schneider B.J. et al. National Comprehensive Cancer Network. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2018;36(17):1714–68. DOI:10.1200/JCO.2017.77.6385; Guidon A.C. Lambert–Eaton myasthenic syndrome, botulism, and immune checkpoint inhibitor-related myasthenia gravis. Continuum (Minneap Minn) 2019;25(6):1785–806. DOI:10.1212/CON.0000000000000807; Basnet A., Sharma N.R., Gautam S. et al. Immune checkpoint inhibitor-induced myasthenia gravis, myocarditis, and myositis: A case report. Clin Case Rep 2024;12(6):e8968. DOI:10.1002/ccr3.8968; Pathak R., Katel A., Massarelli E. et al. Immune checkpoint inhibitor-induced myocarditis with myositis/myasthenia grav is overlap syndrome: A systematic review of cases. Oncologist 2021;26(12):1052–61. DOI:10.1002/onco.13931; https://nmb.abvpress.ru/jour/article/view/649